Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.98
-0.06 (-0.60%)
At close: Dec 15, 2025, 4:00 PM EST
9.98
0.00 (0.00%)
After-hours: Dec 15, 2025, 5:27 PM EST
Immatics Revenue
Immatics had revenue of 5.19M EUR in the quarter ending September 30, 2025, a decrease of -89.74%. This brings the company's revenue in the last twelve months to 84.76M, down -26.62% year-over-year. In the year 2024, Immatics had annual revenue of 155.84M with 188.60% growth.
Revenue (ttm)
84.76M EUR
Revenue Growth
-26.62%
P/S Ratio
12.18
Revenue / Employee
124,277 EUR
Employees
682
Market Cap
1.21B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMTX News
- 4 days ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 10 days ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 4 weeks ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 7 weeks ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 2 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 2 months ago - Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 - Seeking Alpha
- 4 months ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 7 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire